ROCKVILLE, Md.--Celera Genomics and Gemini Research a wholly owned subsidiary of Gemini Holdings, in Cambridge, UK, have formed a collaboration to discover genes and genetic polymorphisms associated with common, chronic, age-related diseases. The collaboration combines Gemini's clinical genetics approach with Celera's DNA sequence information and computational gene discovery capabilities. Gemini's unique method of gene function discovery involves linking genetic differences in a defined population to variations in some 1,500 clinically significant risk traits collected from large numbers of identical and nonidentical twin subjects. The research will focus on those genetic regions or loci that Gemini has previously identified as likely to have genes that influence defined risk traits and, hence, the ultimate manifestation of disease. Under the terms of the agreement, both parties will jointly nominate traits and loci for research into the underlying genetic associations. The two companies intend to commercialize the jointly-owned results of the collaboration by jointly licensing the rights to discoveries to third parties interested in development of gene-based therapeutics and diagnostic products. Both parties will share in the revenues received from licensing fees, milestone payments, and royalties arising from the collaboration.
Celera, Gemini Team Up In Disease Gene Hunt
Sep 10, 1999